SCHEMBL1507727

SCHEMBL1507727

CC(=O)Oc1ccc(C(=NNc2cccc([N+](=O)[O-])c2)c2ccc(OC(C)=O)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.57
MEN1 O00255 10/20 0.57
KMT2A Q03164 10/20 0.57
ALDH1A1 P00352 6/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
HTT P42858 5/20 0.57
PKM P14618 1/20 0.57
ALOX12 P18054 2/20 0.56
HPGD P15428 1/20 0.54
RAB9A P51151 6/20 0.52
GAA P10253 3/20 0.52
MAPK1 P28482 2/20 0.52
NPC1 O15118 5/20 0.49
NPSR1 Q6W5P4 2/20 0.49
BLM P54132 2/20 0.49
RECQL P46063 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
POLB P06746 3/20 0.46
DDX3X O00571 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507639 0.81 ALDH1A1 (0.59) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1507652 0.80 ALDH1A1 (0.58) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL14793650 0.80 ALDH1A1 (0.59) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL13701380 0.80 LMNA (0.47) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL8657109 0.75 MAPT (0.64) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1465069 0.75 MAPT (0.67) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL260595 0.75 MAPT (0.67) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1465068 0.75 MAPT (0.67) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL260597 0.75 MAPT (0.67) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1465067 0.75 MAPT (0.67) MAPTMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305246-B1 Tumor necrosis factor inhibitors UNIV PENNSYLVANIA (US) 2015-08-26 EP disclosed
EP-2305246-B1 Tumor necrosis factor inhibitors UNIV PENNSYLVANIA (US) 2015-08-26 EP disclosed
US-9096607-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-08-04 US disclosed
US-9096607-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-08-04 US disclosed
US-9096607-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-08-04 US disclosed
US-20140256803-A1 TUMOR NECROSIS FACTOR INHIBITORS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-09-11 US disclosed
US-20140256803-A1 TUMOR NECROSIS FACTOR INHIBITORS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-09-11 US disclosed
US-20140256803-A1 TUMOR NECROSIS FACTOR INHIBITORS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-09-11 US disclosed
US-8765810-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-07-01 US disclosed
US-8765810-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-07-01 US disclosed
EP-2305246-A1 Tumor necrosis factor inhibitors Ception Therapeutics, Inc. (US) 2011-04-06 EP disclosed
EP-2298295-A1 Tumor necrosis factor inhibitors Ception Therapeutics, Inc. (US) 2011-03-23 EP disclosed
EP-2298295-A1 Tumor necrosis factor inhibitors Ception Therapeutics, Inc. (US) 2011-03-23 EP disclosed
US-20090221527-A1 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS, INC. (US) 2009-09-03 US disclosed
US-20090221527-A1 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS, INC. (US) 2009-09-03 US disclosed
US-20090221527-A1 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS, INC. (US) 2009-09-03 US disclosed
EP-1845970-A4 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS INC (US) 2009-02-18 EP disclosed
EP-1845970-A2 TUMOR NECROSIS FACTOR INHIBITORS Ception Therapeutics, Inc. (US) 2007-10-24 EP disclosed
WO-2006083970-A2 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS, INC. (US) 2006-08-10 WO disclosed
WO-2006083869-A2 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS, INC. (US) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221527-A1 TUMOR NECROSIS FACTOR INHIBITORS TNFRSF1A, TNF, TNFRSF9 MAPT 3981/4885MEN1 3488/4885KMT2A 4709/4885
US-20140256803-A1 TUMOR NECROSIS FACTOR INHIBITORS TNFRSF1A, TNF, TNFRSF9 MAPT 3981/4885MEN1 3488/4885KMT2A 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.